Gossamer Bio Statistics
Total Valuation
Gossamer Bio has a market cap or net worth of $217.75 million. The enterprise value is $126.11 million.
Important Dates
The next estimated earnings date is Tuesday, May 6, 2025, after market close.
| Earnings Date | May 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Gossamer Bio has 227.22 million shares outstanding. The number of shares has increased by 48.23% in one year.
| Current Share Class | 227.22M |
| Shares Outstanding | 227.22M |
| Shares Change (YoY) | +48.23% |
| Shares Change (QoQ) | +0.11% |
| Owned by Insiders (%) | 3.13% |
| Owned by Institutions (%) | 61.73% |
| Float | 183.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.89 |
| Forward PS | 9.56 |
| PB Ratio | 7.36 |
| P/TBV Ratio | 7.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.88, with a Debt / Equity ratio of 6.88.
| Current Ratio | 6.88 |
| Quick Ratio | 6.66 |
| Debt / Equity | 6.88 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.20 |
Financial Efficiency
Return on equity (ROE) is -122.54% and return on invested capital (ROIC) is -14.76%.
| Return on Equity (ROE) | -122.54% |
| Return on Assets (ROA) | -11.94% |
| Return on Invested Capital (ROIC) | -14.76% |
| Return on Capital Employed (ROCE) | -22.17% |
| Revenue Per Employee | $791,041 |
| Profits Per Employee | -$389,848 |
| Employee Count | 145 |
| Asset Turnover | 0.37 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Gossamer Bio has paid $893,000 in taxes.
| Income Tax | 893,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +35.30% in the last 52 weeks. The beta is 1.88, so Gossamer Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.88 |
| 52-Week Price Change | +35.30% |
| 50-Day Moving Average | 1.13 |
| 200-Day Moving Average | 0.97 |
| Relative Strength Index (RSI) | 49.29 |
| Average Volume (20 Days) | 1,628,631 |
Short Selling Information
The latest short interest is 9.17 million, so 4.04% of the outstanding shares have been sold short.
| Short Interest | 9.17M |
| Short Previous Month | 7.97M |
| Short % of Shares Out | 4.04% |
| Short % of Float | 4.99% |
| Short Ratio (days to cover) | 5.88 |
Income Statement
In the last 12 months, Gossamer Bio had revenue of $114.70 million and -$56.53 million in losses. Loss per share was -$0.25.
| Revenue | 114.70M |
| Gross Profit | 114.70M |
| Operating Income | -59.92M |
| Pretax Income | -172.58M |
| Net Income | -56.53M |
| EBITDA | -59.09M |
| EBIT | -59.92M |
| Loss Per Share | -$0.25 |
Full Income StatementBalance Sheet
The company has $294.52 million in cash and $202.88 million in debt, giving a net cash position of $91.64 million or $0.40 per share.
| Cash & Cash Equivalents | 294.52M |
| Total Debt | 202.88M |
| Net Cash | 91.64M |
| Net Cash Per Share | $0.40 |
| Equity (Book Value) | 29.49M |
| Book Value Per Share | 0.13 |
| Working Capital | 264.88M |
Full Balance SheetCash Flow
| Operating Cash Flow | -3.47M |
| Capital Expenditures | n/a |
| Free Cash Flow | -3.47M |
| FCF Per Share | -$0.02 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -52.24% and -49.28%.
| Gross Margin | 100.00% |
| Operating Margin | -52.24% |
| Pretax Margin | -48.50% |
| Profit Margin | -49.28% |
| EBITDA Margin | -51.51% |
| EBIT Margin | -52.24% |
| FCF Margin | n/a |
Dividends & Yields
Gossamer Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -48.23% |
| Shareholder Yield | n/a |
| Earnings Yield | -25.96% |
| FCF Yield | -1.59% |
Analyst Forecast
The average price target for Gossamer Bio is $7.50, which is 682.64% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.50 |
| Price Target Difference | 682.64% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 25.74% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Gossamer Bio has an Altman Z-Score of -4.45 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.45 |
| Piotroski F-Score | 2 |